Clinical Research Directory

Inclusion Criteria: * Patients are females with histologically proven carcinoma of the breast * The carcinoma of the breast is a local disease with limited size (but tumor size ≥ 0.5cm) and in the multidisciplinary tumor board meeting breast conserving therapy is advised. * Age ≥ 18 years * Written informed consent has been obtained * Women of childbearing potential (premenopausal women with intact reproductive organs and women less than two years after menopause) require use of effective contraception at least 3 months before administration of the tracer (if not, a negative serum pregnancy test has to be submitted), and they need to be willing to ensure that she or her partner uses effective contraception during the trial and for 3 months thereafter. Exclusion Criteria: * Medical or psychiatric conditions that compromise the patient's ability to give informed consent * Non palpable breast tumor or prior surgery of this breast * Received an investigational drug within 30 days prior to bevacizumab-IRDye800CW * History of myocardial infarction, cerebrovascular accident, uncontrolled cardiac heart failure or unstable angina within 6 months prior to enrollment * Inadequately controlled hypertension with or without current antihypertensive medication * Significant renal or hepatic impairment (grade II or higher deviations by CTCAE) * History of allergy or infusion reactions bevacizumab or other monoclonal antibodies * Pregnant or lactating women * Patients receiving Class IA (quinidine, procainamide) or Class III (dofetilide, amiodarone, sotalol) antiarrhythmic agents * Life expectancy \< 12 weeks * Preoperatively undetectable lymph nodes using SPECT-scan, requiring the use of patent blue